Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “ixazomib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 32
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 32 pipeline programs matching "ixazomib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

32 results for “ixazomib” Back to intelligence hub

Search results

Page 1 of 2
  1. HM16/047

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  2. IXAZOMIB

    Takeda

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 3 small molecule terminated

    1 trial
  3. Ixazomib

    Takeda

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  4. Ixazomib Citrate

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials
  5. MyelomaXIV

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  6. IXAZOMIB

    Takeda

    Follicular Lymphoma

    phase 2 small molecule completed

    1 trial
  7. Ixazomib

    Takeda

    Multiple Myeloma

    phase 2 small molecule completed

    15 trials
  8. Ixazomib

    Takeda

    ALL, Childhood

    phase 2 small molecule active

    1 trial
  9. Ixazomib

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial
  10. Ixazomib

    Takeda

    Mantle Cell Lymphoma

    phase 2 small molecule active

    2 trials
  11. Ixazomib

    Takeda

    Myeloid Hematologic Malignancy

    phase 2 small molecule completed

    1 trial
  12. Ixazomib

    Takeda

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial
  13. Ixazomib

    Takeda

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule terminated

    1 trial
  14. Ixazomib

    Takeda

    Smoldering Multiple Myeloma

    phase 2 small molecule completed

    1 trial
  15. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 small molecule terminated

    1 trial
  16. Ixazomib 1 MG

    Takeda

    Human Immunodeficiency Virus (HIV)

    phase 2 small molecule completed

    1 trial
  17. Ixazomib/Pomalidomide/Dexamethasone

    Takeda

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial
  18. MyDRUG (MMRC-085)

    Karyopharm Therapeutics Inc

    Relapsed Refractory Multiple Myeloma

    phase 2 small molecule completed

    1 trial
  19. ΕΑΕ-2018/ΜΜ03

    Takeda

    Multiple Myeloma

    phase 2 small molecule active

    1 trial
  20. IXAZOMIB

    Takeda

    Advanced Non-hematologic Malignancies

    phase 1 small molecule completed

    1 trial
  21. IXAZOMIB

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial
  22. Ixazomib

    Takeda

    Lupus Nephritis

    phase 1 small molecule terminated

    1 trial
  23. Ixazomib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial
  24. Ixazomib

    Takeda

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.